Please assess the completion status of the following clinical trial:

Trial Title: A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific requirements~* Women of childbearing potential must have a negative pregnancy test, be non-lactating, and be using a highly effective form of birth control for 3 months prior to enrollment, during the study, and for 3 months after completion of all study-related proceed~* Male volunteers must be willing to use barrier contraception from the first day of dosing until 3 months after the last dose of IP.~* Have a body mass index (BMI) between 18 and 30 kg/m2, and weigh at least 50 kg~* Healthy male and/or female volunteers between the ages of 18 to 75 years inclusive, with veins on the back of both hands and both forearms suitable for cannulation or repeated venipuncture.~Exclusion Criteria:~* Use of any other investigational compound or participation in another clinical trial within 1 month prior to first administration of IP in this study~* History of any clinically significant disease or disorder (e.g., neurological, haematological, psychiatric, gastrointestinal, hepatic, renal disease)~* Positive serology result on screening for serum hepatitis B surface antigen, hepatitis C antibody (HCV), or human immunodeficiency virus (HIV)~* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs~* Any clinically significant abnormalities in the physical examination, lab, 12-lead ECG or vital signs as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): 600 mg ceftaroline fosamil in 50 ml infusion volume
- B (Type: PLACEBO_COMPARATOR): Placebo in 50 ml infusion volume
- C (Type: EXPERIMENTAL): 600 ceftaroline fosamil in 250 ml infusion volume
- D (Type: PLACEBO_COMPARATOR): Placebo in 250 ml infusion volume
- E (Type: EXPERIMENTAL): 600 mg ceftaroline in 100 ml infusion volume
- F (Type: PLACEBO_COMPARATOR): Placebo in 100 ml infusion volume

Based on this trial design, predict the completion outcome and termination type (if applicable).